1.05 USD
▼-0.12-10.26%
盘后 1.07 +1.90%
2026-11-20
市值
$1.31M
市盈率
0.00
EPS
4469.19
股息率
—
52 周区间
1.00 – 434.40
成交量
40.97K
Beta
1.61
目标价
—
52W 低 1.0052W 高 434.40
价格走势
公司简介
Enlivex Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. It offers AllocetraTM, a cell therapy designed to restore macrophage homeostasis, as well as develops AllocetraTM intra-articular injection for the treatment of knee osteoarthritis, which is in phase 1/2 trial; intra-articular AllocetraTM in osteoarthritis of the temporomandibular joint (TMJ); and Allocetra-OTS for the treatment of organ failure in adult sepsis patients, which is in phase 2. Enlivex Ltd. was forme...